Q-omics provides the consensus-scored C9orf16 profile across patient tissues and cancer cell-line models. C9orf16 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, C9orf16 is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, C9orf16 RNA expression shows 19,192 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, THCA, and THYM as cancer lineages where C9orf16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C9orf16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C9orf16 survival associations across molecular data types. C9orf16 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C9orf16 RNA expression–survival associations across cancer types. High C9orf16 expression shows unfavorable associations in ACC, KIRC, UCS, LAML and LIHC, but favorable associations in LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for C9orf16 RNA expression.
This table summarizes C9orf16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C9orf16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C9orf16 shows higher tumor expression in THCA, COAD, LIHC, KIRP, STAD and UCEC. The THCA box plot shows higher C9orf16 RNA expression in tumor versus normal tissue (log2 FC = +1.607, t-test p < 0.001).
This table shows molecular features associated with C9orf16 in patient tissues and cancer cell lines. In patient samples, C9orf16 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, C9orf16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
